30 closest matches · ranked by relevance
Endocrine System Diseases
Primary: Change From Baseline in Annual Growth Rate Standard Deviation Score (SDS) for Chronological Age (CA) at Month 36 in Intent-to-Treat (ITT) Population — -1.29; 2.36 SDS
Short Stature
Primary: Height Standard Deviation Score — -2.52; -1.57; -1.19; -1.09 standard deviation score
HIV Lipodystrophy
Primary: Overnight Mean Growth Hormone Secretion After 2 Weeks of Study Drug — 0.23; 0.07; 1.24 ng/mL — p=0.01
Heart Failure · Growth Hormone Deficiency · Ischemic Heart Disease
Primary: Peak VO2 — 14.5; 12.9 ml/kg/min
Obesity
Primary: HsCRP — -1.1; 0.5; -1.3; -0.3 mg/L
Fibromyalgia
Primary: Percentage of Participants With Less Than 11 Tender Points at Month 6 — 20; 22 Percentage of participants
Growth Hormone Deficiency · Panhypopituitarism · Short Stature
Primary: Reactive Hyperemic Response After 3 Months of Growth Hormone — 21.077 ml/dl min — p=0.644
Growth Disorders · Insulin-Like Growth Factor-1 Deficiency
Primary: Height Velocity During the First Year - Intent to Treat (ITT)Population — 5.2; 6.9; 7.7 cm/yr — p=<0.0001
Diabetes · Metabolic Syndrome · Insulin Resistance
Primary: Insulin Sensitivity — 3.06; 3.33 units on a scale
AIDS · HIV Infections
Primary: Change in Visceral Adipose Tissue Area From Baseline to 18 Months — -22; -4 centimeters squared — p=0.049
Infant, Small for Gestational Age
Primary: Change From Baseline in Height Standard Deviation Score (SDS) at Month 24. — 1.63; 0.43 SDS — p=<0.001
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
Hypopituitarism
Primary: BOLD Signal Measured by Functional MRI Scan to Functional Connectivity Measured by fMRI
Acromegaly · Type 2 Diabetes Mellitus
Primary: Percentage With Growth Hormone (GH) Suppression to < 0.4 ng/ml — 0; 7; 8 Participants
Prader-Willi Syndrome
Primary: Body Composition — 51.2; 48.5; 52.1 percentage of body fat — p=<0.05
Anorexia Nervosa · Osteopenia · Osteoporosis
Primary: Bone Metabolism — 34.3; 10.4 ng/ml
Phelan McDermid Syndrome
Primary: ABC - Social Withdrawal Subscale — 10.31; 4.6; 14.8; 6.2 score on a scale
Growth Disorders · Intrauterine Growth Retardation
Primary: Change From Baseline in Annual Growth Rate Measured at 2 Years Following Treatment With Genotonorm — 3.07; 3.97; 2.84 cm/year — p=0.02922
Obesity · Osteopenia
Primary: Bone Mineral Density — -0.015; -0.008 grams/cm^2
Osteogenesis Imperfecta
Primary: Proportion of Subjects Who Met Criteria of Increase in Growth Rate Since Baseline. — 25 Participants
Turner's Syndrome
Primary: Height SDS at Year 4 — -1.35; -2.44 standard deviation score
Foetal Growth Problem · Small for Gestational Age
Primary: Change in Height Standard Deviation Score (SDS) for Chronological Age (CA) at Week 260 - Subjects Received NN220 Treatment for 5 Years — -2.9488; -2.9047; 1.2066; 2.0247…
Crohn's Disease
Primary: Crohn's Disease Histologic Index of Severity (CDHIS) — 7; 8; 6; 8 scores on a scale
Acromegaly · Growth Hormone Deficiency · Pituitary Disease
Primary: Change in High-sensitivity C-reactive Protein — 2.93; 3.23; -0.36; 1.64 mg/liter
Obese · Growth Hormone Secretion Abnormality
Primary: Phosphocreatine Recovery — 0.74 correlation coefficient — p=0.02
Obesity
Primary: 24 Hour Average Plasma Growth Hormone Concentration — 0.4; 1.2; 4.1 ng/mL
Turner Syndrome
Primary: Total Brain Volume — 18.22; 19.78 percentage change
Obesity
Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70
Growth Hormone Therapy · Infant, Very Low Birth Weight
Primary: Change in Height Standard Deviation Score (SDS) After 1 Year — 1.099; 0.108 centimeters — p=<0.001
Children Born With Serious Intra-uterine Growth Retardation
Primary: Final Height — 145.90; 150.06; 153.27; 155.59 cm